doi:10.19983/j.issn.2096-8493.2024052

Abstract

CLC Number:

References 23

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1):15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	王家祥, 苟建军, 赵菁. 综合医院多学科协作在疾病诊治中的实践与作用. 医学与哲学, 2015, 36(9B):1-4.
[3]	卢水华. 关注结核病共患病已成为公共卫生的需要. 结核与肺部疾病杂志, 2022, 3(4):255-260. doi:10.19983/j.issn.2096-8493.20220107.
[4]	Huang Z, LaCourse SM, Kay AW, et al. CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children,including children with HIV: a molecular diagnostics study. Lancet Microbe, 2022, 3(7): e482 -e492.doi:10.1016/S26665247(22) 00087-8.
[5]	舒薇, 刘宇红. 精进臻善惟实励新:世界卫生组织《2022年全球结核病报告》解读. 中国防痨杂志, 2023, 45(5):454-457. doi:10.19982/j.issn.1000-6621.20230102.
[6]	王瑾, 卢水华. 结核病学科建设:从临床资源型向医学科研型转化. 中国防痨杂志, 2023, 45(12):1125-1130. doi:10.19982/j.issn.1000-6621.20230353.
[7]	Wallis RS, Ginindza S, Beattie T, et al. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective,open-label,phase 2,randomised controlled trial. Lancet Respir Med, 2021, 9 (8):897-908. doi:10.1016/S2213-2600(20) 30448-3.
[8]	董佳欣, 赵爱华, 夏焕章, 等. 《世界卫生组织新型结核病疫苗首选产品特性》的解读与思考. 中国防痨杂志, 2023, 45(11):1016-1020. doi:10.19982/j.issn.1000-6621.20230318.
[9]	Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis:a meta-analysis. Sci Rep, 2017, 7(1):1090. doi:10.1038/s41598-017-01213-5.
[10]	Leung CC, Yew WW, Mok TYW, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology, 2017, 22(6):1225-1232. doi:10.1111/resp.13017. pmid: 28244689
[11]	林岩, 邓国防. 糖尿病并发结核病治疗中多学科合作应注意的问题. 中国防痨杂志, 2021, 43(7):649-652. doi:10.3969/j.issn.1000-6621.2021.07.002.
[12]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1): 12-22. doi:10.3969/j.issn.1000-6621.2021.01.004.
[13]	Huang CC, Chu AL, Becerra MC, et al. Mycobacterium tuberculosis Beijing Lineage and Risk for Tuberculosis in Child Household Contacts, Peru. Emerg Infect Dis, 2020, 26(3):568-578. doi:10.3201/eid2603.191314.
[14]	牛海军, 李远春, 赵雁林, 等. 河南省南阳市276例非结核分枝杆菌肺病的临床特征及其耐药性分析. 疾病监测, 2021, 36(7):708-713. doi:10.3784/jbjc.202101290055.
[15]	Özen N, Kula Atik T, Çetin Duran A. Klinik Örneklerden İzole Edilen Mycobacterium tuberculosis Kültür ve İlaç Duyarlılık Test Sonuçlarının Analizi ve Tüberküloz Dışı Mikobakterilerin Dagˇılımının İncelenmesi [Evaluation of Mycobacterium tuberculosis Culture and Drug Susceptibility Test Results and the Distribution of Nontuberculosis Mycobacteria from the Clinical Specimens]. Mikrobiyol Bul, 2020,54(4):559-574. Turkish. doi:10.5578/mb.70088.
[16]	王晨倩, 王桂荣, 姜广路, 等. 鸟分枝杆菌复合群对氯法齐明、贝达喹啉和德拉马尼的药物敏感性. 实用医学杂志, 2022, 38(6):691-695. doi:10.3969/j.issn.1006-5725.2022.06.008.
[17]	Bagcchi S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe, 2023, 4(1):e20. doi:10.1016/S2666-5247(22)00359-7.
[18]	Qi TK, Chen J, Zhang RF, et al. A retrospective cohort study of early mortality among patients with HIV/TB co-infection in Shanghai municipality. HIV Med, 2020, 21(11):739-746. doi:10.1111/hiv.13025. pmid: 33369033
[19]	吴雪韵, 沈银忠. 人类免疫缺陷病毒与结核分枝杆菌合并感染发病机制的研究进展. 内科理论与实践, 2019, 14(4):253-258. doi:10.16138/j.1673-6087.2019.04.011.
[20]	中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版). 协和医学杂志, 2022, 13(2): 203-226. doi:10.12290/xhyxzz.2022-0097.
[21]	中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识. 中华传染病杂志, 2022, 40(1):6-19. doi:10.3760/cma.j.cn311365-20211105-00387.
[22]	World Health Organization. Treatment of drug-susceptible tuberculosis: rapid communication. Geneva: World Health Organization, 2021.
[23]	路希维. 注重多学科合作推进结核病整合医学发展. 中国防痨杂志, 2021, 43(2):105-106. doi:10.3969/j.issn.1000-6621.2021.02.001.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 23

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101.
[2]	Zhang Ying, Guo Chunhui. Research progress in the treatment of tuberculous tracheobronchial stenosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 87-93.
[3]	Yan Wenhua, Chen Wenjun. The value of digital health education in the preventive management of caregivers of patients with bacterial positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 73-78.
[4]	Gu Jinhua, Zhang Panpan. Evaluation of the application value of three detection methods for Mycobacterium tuberculosis in a comprehensive hospital [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 68-72.
[5]	Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60.
[6]	Qi Wei, Zhao Enyi. The epidemic characteristics and the trends of pulmonary tuberculosis in elderly and non-elderly in central urban area, Tianjin from 2006 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 46-54.
[7]	Yang Yan, Dong Wen, Chen Jianjun, Zhang Yu. Epidemiologic characteristics of pulmonary tuberculosis in Zhuxi County, Shiyan City (2014-2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 40-45.
[8]	Zheng Jianli, Wu Yumei, Zhang Shili, Du Zixian, Li Turong, Chen Shisheng, Lin Wenge. Cost-effectiveness analysis of active tuberculosis screening among high-risk populations in Longyan City, Fujian Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 35-39.
[9]	Zhao Yongnian, Zhang Lijie, Wang Tongmin. Analysis of the epidemiological characteristics of reported pulmonary tuberculosis in Xinjiang Production and Construction Corps, 2014—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 30-34.
[10]	Wan Ying, Pang Xuewen, Zhang Fan. Evaluation on effect of health promotion for tuberculosis prevention and control in Tianjin City from 2010 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 22-29.
[11]	Chen Yu, Li Xiaorui, Wang Miaoran, Zhang Yuqi, Liu Chang, Wang Zhaohua, Shi Jie, Fan Lichao, Yin Zhihua, Xie Jianping. The research progress on the role of metal ions in tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 102-112.
[12]	Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67.
[13]	Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13.
[14]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 495-499.
[15]	Hu Xinyang, Gao Jingtao. Interpretation of WHO global tuberculosis report 2024 [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 500-504.